Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Evoq RemediesBOM:543500 59 Net Debt Paydown Yield % is 60.11% as of Aug. 20, 2026, which is 1363% above its 10-year median of 4.11. GuruFocus rates BOM:543500 with a GF Score™ of 59/100 and a GF Value™ of ₹12.88 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 105 Medical Distribution companies, Evoq Remedies ranks better than 96.19% on this metric.
Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt.
As of today, Evoq Remedies's Net Debt Paydown Yield % was 60.11%.
Evoq Remedies (BOM:543500) Net Debt Paydown Yield % Explanation
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.
In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.
Evoq Remedies Net Debt Paydown Yield % Related Terms
Evoq Remedies Net Debt Paydown Yield % Historical Data
* Premium members only.
The historical data trend for Evoq Remedies's Net Debt Paydown Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:543500 vs MCK, COR, CAH: Net Debt Paydown Yield % Comparison
For the Medical Distribution subindustry, Evoq Remedies's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evoq Remedies Net Debt Paydown Yield % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Evoq Remedies's Net Debt Paydown Yield % distribution charts can be found below:
* The bar in red indicates where Evoq Remedies's Net Debt Paydown Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
What does a Net Debt Paydown Yield % of 60.11% mean?
Evoq Remedies (BOM:543500) has a Net Debt Paydown Yield % of 60.11% as of Aug. 20, 2026. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Evoq Remedies and its competitors. This is 1363% above median its historical median of 4.11. According to the industry distribution chart, Evoq Remedies ranks #4 out of 105 companies in the Medical Distribution industry, placing it in the top 3.8%.
Is Evoq Remedies' Net Debt Paydown Yield % too high?
Evoq Remedies' current Net Debt Paydown Yield % of 60.11% is 1363% above median its 10-year median of 4.11. The Medical Distribution industry median Net Debt Paydown Yield % is 0.10. Evoq Remedies' value of 60.11% is 60010% above this industry median. Based on the distribution chart, Evoq Remedies ranks #4 out of 105 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Evoq Remedies has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evoq Remedies' Net Debt Paydown Yield % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Evoq Remedies ranks #4 out of 105 companies for Net Debt Paydown Yield %. This places Evoq Remedies in the top 4% of its industry — outperforming the majority of peers. The industry median Net Debt Paydown Yield % is 0.10. Evoq Remedies' value of 60.11% is 60010% above this benchmark. While the company's 10-year median is 4.11 vs. the industry median of 0.10, Evoq Remedies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Debt Paydown Yield % for a Medical Distribution company?
The median Net Debt Paydown Yield % among Medical Distribution companies is 0.10, based on 105 companies in the industry. Companies in the top quartile (top 25%) have a Net Debt Paydown Yield % significantly above this median, while those in the bottom quartile fall well below. However, Net Debt Paydown Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Evoq Remedies's current Net Debt Paydown Yield % of 60.11% is 60010% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Debt Paydown Yield % mean?
A high Net Debt Paydown Yield % can signal that a stock is expensive relative to its fundamentals. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Evoq Remedies and its competitors. For the Medical Distribution industry, the median Net Debt Paydown Yield % is 0.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evoq Remedies's current Net Debt Paydown Yield % is 60.11%, which is 1363% above median its own 10-year median of 4.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evoq Remedies stock overvalued right now?
Based on GuruFocus' analysis, Evoq Remedies (BOM:543500) is currently considered Possible Value Trap. The stock's GF Value™ is ₹12.88, compared to a current price of ₹1.80 — trading 86% below its estimated fair value. The current Net Debt Paydown Yield % is 60.11%, which is 1363% above median its 10-year median of 4.11 and 60010% above the Medical Distribution industry median of 0.10. Evoq Remedies' overall GF Score™ is 59/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Debt Paydown Yield % calculated?
Net Debt Paydown Yield % is calculated from a company's financial statements. For Evoq Remedies (BOM:543500), the current Net Debt Paydown Yield % is 60.11% as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Evoq Remedies (BOM:543500) Overvalued in 2026?
Based on GuruFocus' analysis, Evoq Remedies stock appears to be undervalued.
The current stock price of ₹1.80 is trading 86% below its estimated GF Value™ of ₹12.88.
GuruFocus considers Evoq Remedies to be Possible Value Trap.
Key valuation signals for BOM:543500:
Net Debt Paydown Yield %: 60.11% (1363% above median its 10-year median of 4.11)
GF Value™: ₹12.88 vs. price of ₹1.80 (86% below fair value)
Industry Position: 60010% above the Medical Distribution median (#4 of 105)
No single metric tells the full story. See the BOM:543500 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Evoq Remedies Ltd is engaged in the pharmaceutical business involving marketing, trading, and distribution of wide range of pharmaceutical formulation products such as anti-biotic drugs, calcium, multivitamins, injections, and others. It operates in a single segment that is Pharmaceutical Trading.
59GF Score
Get the complete analysis for BOM:543500
Net Debt Paydown Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543500 has been successfully added to your 
